Thérèse Rachell Theodoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thérèse Rachell Theodoro has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Maria Aparecida Silva Pinhal
Department of Biochemistry, FMABC University Center, Santo André, SP, 09060-650, Brazil
5 shared publications - Fátima Solange Pasini
Oncology and Radiology Department, Laboratory of Medical Investigation 24 (LIM 24), University of São Paulo, Medical School, São Paulo, Brazil
3 shared publications - Leandro Luongo Matos
Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Universidade de São Paulo (Icesp HCFMUSP). Professor, Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil
3 shared publications - Luiz Paulo Kowalski
Head and Neck Surgery Department University of São Paulo Medical School (FMUSP) São Paulo Brazil
3 shared publications - Ana Kober Nogueira Leite
Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Albert Einstein, São Paulo, Brazil
2 shared publications - Bianca Bianco
Centro Universitário FMABC, Santo Andre, SP, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 26, eAO2153
Immunoexpression of stem cell markers CD44, CD133, ALDH1-2, and LGR5 in colorectal carcinoma and their association with clinicopathological tumor characteristics
To investigate the association of CD44, CD133, ALDH1-2, and LGR5 expression with clinicopathological tumor variables. Twenty-eight adult patients with colorectal carcinoma who underwent curative surgery were included in the study. Paraffin-embedded samples were subjected to immunohistochemical staining with anti-CD44, anti-CD133, anti-ADLH1-2, and anti-LGR5 antibodies, and the results were compared with the patients' clinicopathological variables. P-values 60 years of age, in the rectum and right colon, and in the presence of lymph node involvement. CD44 protein expression was increased in tumors of the left colon. Increased tissue levels of ALDH1-2 and LGR5 were related to increased aggressiveness of colorectal carcinoma.
- 28 May 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 26, eAO2153
Open AccessImmunoexpression of stem cell markers CD44, CD133, ALDH1-2, and LGR5 in colorectal carcinoma and their association with clinicopathological tumor characteristics
To investigate the association of CD44, CD133, ALDH1-2, and LGR5 expression with clinicopathological tumor variables. Twenty-eight adult patients with colorectal carcinoma who underwent curative surgery were included in the study. Paraffin-embedded samples were subjected to immunohistochemical staining with anti-CD44, anti-CD133, anti-ADLH1-2, and anti-LGR5 antibodies, and the results were compared with the patients' clinicopathological variables. P-values 60 years of age, in the rectum and right colon, and in the presence of lymph node involvement. CD44 protein expression was increased in tumors of the left colon. Increased tissue levels of ALDH1-2 and LGR5 were related to increased aggressiveness of colorectal carcinoma.
- Open Access
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 94
MicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma
Purpose: Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation. Methods: From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression ( P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering. Results: The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness ( P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p ( P < 0.001) and miR-19b-3p ( P < 0.001), and lower expression of miR-31-5p ( P = 0.004) and let-7e-5p ( P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression. Conclusions: Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 94
Open AccessMicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma
Purpose: Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation. Methods: From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression ( P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering. Results: The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness ( P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p ( P < 0.001) and miR-19b-3p ( P < 0.001), and lower expression of miR-31-5p ( P = 0.004) and let-7e-5p ( P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression. Conclusions: Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (4) , 1-9
MicroRNA expression signatures associated with metastatic progression in papillary thyroid carcinoma
The objective of this study is to compare the miRNA expression profiles of primary tumors and matched metastatic lesions from patients who died due to progression of metastatic PTC. We conducted an exploratory study of patients with PTC who died from disease progression and had tissue samples available from both primary tumors and distant metastases. Total RNA was extracted and analyzed to assess the expression of 64 preselected miRNAs. Expression data were normalized using endogenous controls (let-7g-5p and miR-181a-5p), and differential expression was calculated using the 2-∆Ct method. Those miRNAs detected in < 70% of samples or with cycle threshold (Ct) > 36 were excluded. Univariate analyses were performed using paired tests, and multivariate results were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method. Out of 3,555 patients treated for PTC between 1986 and 2015, eight patients were included. Univariate analysis identified five miRNAs differentially expressed in metastatic lesions: let-7e-5p, miR-10b-5p, miR-30e-3p, miR-423-5p, and miR-483-3p. After multivariate adjustment, miR-10b-5p and miR-30e-3p remained independently overexpressed in metastatic tissues. This study is one of the first to demonstrate distinct miRNA expression profiles in metastatic versus primary tumors in fatal PTC cases. The identified miRNAs are known to regulate processes such as cell migration, invasion, and apoptosis in other cancers, suggesting their potential contribution to PTC metastasis.
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (4) , 1-9
Open AccessMicroRNA expression signatures associated with metastatic progression in papillary thyroid carcinoma
The objective of this study is to compare the miRNA expression profiles of primary tumors and matched metastatic lesions from patients who died due to progression of metastatic PTC. We conducted an exploratory study of patients with PTC who died from disease progression and had tissue samples available from both primary tumors and distant metastases. Total RNA was extracted and analyzed to assess the expression of 64 preselected miRNAs. Expression data were normalized using endogenous controls (let-7g-5p and miR-181a-5p), and differential expression was calculated using the 2-∆Ct method. Those miRNAs detected in < 70% of samples or with cycle threshold (Ct) > 36 were excluded. Univariate analyses were performed using paired tests, and multivariate results were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method. Out of 3,555 patients treated for PTC between 1986 and 2015, eight patients were included. Univariate analysis identified five miRNAs differentially expressed in metastatic lesions: let-7e-5p, miR-10b-5p, miR-30e-3p, miR-423-5p, and miR-483-3p. After multivariate adjustment, miR-10b-5p and miR-30e-3p remained independently overexpressed in metastatic tissues. This study is one of the first to demonstrate distinct miRNA expression profiles in metastatic versus primary tumors in fatal PTC cases. The identified miRNAs are known to regulate processes such as cell migration, invasion, and apoptosis in other cancers, suggesting their potential contribution to PTC metastasis.
- Open Access
- 22 September 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAO1421
Expression profiles of miR-23a andmiR-146a in the peripheral blood of women with premature ovarian insufficiency
INTRODUCTION Premature ovarian insufficiency (POI) is a clinical syndrome characterized by oligo/amenorrhea observed in women before the age of 40 years, lasting at least 4 months, with elevated follicle-stimulating hormone (FSH) levels.() Its diagnosis is confirmed by two serum measurements conducted at least 1 month apart that show high FSH levels (>25IU/L) and low estradiol levels.() The condition is caused by varying factors, including genetic, immunological, or metabolic factors; iatrogenic intervention; and environmental toxins. The reason is idiopathic in 90%
- 22 September 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAO1421
Open AccessExpression profiles of miR-23a andmiR-146a in the peripheral blood of women with premature ovarian insufficiency
INTRODUCTION Premature ovarian insufficiency (POI) is a clinical syndrome characterized by oligo/amenorrhea observed in women before the age of 40 years, lasting at least 4 months, with elevated follicle-stimulating hormone (FSH) levels.() Its diagnosis is confirmed by two serum measurements conducted at least 1 month apart that show high FSH levels (>25IU/L) and low estradiol levels.() The condition is caused by varying factors, including genetic, immunological, or metabolic factors; iatrogenic intervention; and environmental toxins. The reason is idiopathic in 90%
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 34 (4) , e1637
PRESENÇA DO PAPILOMAVIRUS HUMANO TIPO 16 E EXPRESSÃO GÊNICA DA PROTEÍNA P16INK4A E ONCOPROTEÍNA E7 NO CARCINOMA COLORRETAL
RESUMO - INTRODUÇÃO: O papilomavírus humano (HPV) é agente das doenças sexualmente transmissíveis de maior prevalência no mundo que estão associadas ao câncer do colo do útero e canal anal. A ação do HPV na carcinogênese colorretal não está ainda estabelecida. OBJETIVO: Estudar a eventual correlação entre a presença do HPV tipo 16 e a expressão gênica da proteína p16INK4a e da oncoproteína E7 de HPV e de seus níveis no tecido do carcinoma colorretal. METODOS: Estudo retrospectivo caso-controle de 79 doentes com carcinoma colorretal divididos em dois grupos: HPV presente e HPV ausente. Foi realizada reação em cadeia da polimerase (PCR), além da hibridização do tipo dot blot para o HPV 16 e o HPV 18 Amostras do tecido colorretal também foram submetidas ao estudo imuno-histoquimico para avaliar o nível tecidual das proteínas E7 e p16INK4a. RESULTADOS: O HPV foi identificado em 36 (45,6%) casos. Não houve diferença significante entre os grupos quanto ao sexo (p=0,056), idade (p=0,1), localização cólica e/ou retal (0,098) e presença do HPV. A expressão gênica da oncoproteína E7 de HPV estava presente em 3,12% dos casos (p=0,9) e a expressão da proteína p16INK4a foi observada em 46,3% (p=0,27) dos indivíduos com detecção do HPV. CONCLUSÃO: A expressão gênica e os níveis teciduais da oncoproteína E7 e da proteína p16INK4a encontrados nos pacientes positivos para o HPV sugerem a ausência de atividade oncogênica do HPV tipo 16 no carcinoma colorretal.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 34 (4) , e1637
Open AccessPRESENÇA DO PAPILOMAVIRUS HUMANO TIPO 16 E EXPRESSÃO GÊNICA DA PROTEÍNA P16INK4A E ONCOPROTEÍNA E7 NO CARCINOMA COLORRETAL
RESUMO - INTRODUÇÃO: O papilomavírus humano (HPV) é agente das doenças sexualmente transmissíveis de maior prevalência no mundo que estão associadas ao câncer do colo do útero e canal anal. A ação do HPV na carcinogênese colorretal não está ainda estabelecida. OBJETIVO: Estudar a eventual correlação entre a presença do HPV tipo 16 e a expressão gênica da proteína p16INK4a e da oncoproteína E7 de HPV e de seus níveis no tecido do carcinoma colorretal. METODOS: Estudo retrospectivo caso-controle de 79 doentes com carcinoma colorretal divididos em dois grupos: HPV presente e HPV ausente. Foi realizada reação em cadeia da polimerase (PCR), além da hibridização do tipo dot blot para o HPV 16 e o HPV 18 Amostras do tecido colorretal também foram submetidas ao estudo imuno-histoquimico para avaliar o nível tecidual das proteínas E7 e p16INK4a. RESULTADOS: O HPV foi identificado em 36 (45,6%) casos. Não houve diferença significante entre os grupos quanto ao sexo (p=0,056), idade (p=0,1), localização cólica e/ou retal (0,098) e presença do HPV. A expressão gênica da oncoproteína E7 de HPV estava presente em 3,12% dos casos (p=0,9) e a expressão da proteína p16INK4a foi observada em 46,3% (p=0,27) dos indivíduos com detecção do HPV. CONCLUSÃO: A expressão gênica e os níveis teciduais da oncoproteína E7 e da proteína p16INK4a encontrados nos pacientes positivos para o HPV sugerem a ausência de atividade oncogênica do HPV tipo 16 no carcinoma colorretal.
- 1 November 2020
- Published by Elsevier in Oral Oncology
- Vol. 110, 104909
Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma
- 1 November 2020
- Published by Elsevier in Oral Oncology
- Vol. 110, 104909
Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma
- 8 May 2019
- Published by Springer Nature in European Spine Journal
- Vol. 28 (6) , 1413-1422
Molecular alterations of human lumbar yellow ligament related to the process of intervertebral disk degeneration and stenosis
The objective of this study was to analyze the layers of yellow ligament in lumbar canal stenosis and disk herniation.
- 8 May 2019
- Published by Springer Nature in European Spine Journal
- Vol. 28 (6) , 1413-1422
Molecular alterations of human lumbar yellow ligament related to the process of intervertebral disk degeneration and stenosis
The objective of this study was to analyze the layers of yellow ligament in lumbar canal stenosis and disk herniation.
- Open Access
- 1 October 2016
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 91 (5) , 595-600
Expression of heparanase in basal cell carcinoma and squamous cell carcinoma
Heparanase is an enzyme that cleaves heparan sulfate chains. Oligosaccharides generated by heparanase induce tumor progression. Basal cell carcinoma and squamous cell carcinoma comprise types of nonmelanoma skin cancer. Evaluate the glycosaminoglycans profile and expression of heparanase in two human cell lines established in culture, immortalized skin keratinocyte (HaCaT) and squamous cell carcinoma (A431) and also investigate the expression of heparanase in basal cell carcinoma, squamous cell carcinoma and eyelid skin of individuals not affected by the disease (control). Glycosaminoglycans were quantified by electrophoresis and indirect ELISA method. The heparanase expression was analyzed by quantitative RT-PCR (qRTPCR). The A431 strain showed significant increase in the sulfated glycosaminoglycans, increased heparanase expression and decreased hyaluronic acid, comparing to the HaCaT lineage. The mRNA expression of heparanase was significantly higher in Basal cell carcinoma and squamous cell carcinoma compared with control skin samples. It was also observed increased heparanase expression in squamous cell carcinoma compared to the Basal cell carcinoma. The glycosaminoglycans profile, as well as heparanase expression are different between HaCaT and A431 cell lines. The increased expression of heparanase in Basal cell carcinoma and squamous cell carcinoma suggests that this enzyme could be a marker for the diagnosis of such types of non-melanoma cancers, and may be useful as a target molecule for future alternative treatment.
- 1 October 2016
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 91 (5) , 595-600
Open AccessExpression of heparanase in basal cell carcinoma and squamous cell carcinoma
Heparanase is an enzyme that cleaves heparan sulfate chains. Oligosaccharides generated by heparanase induce tumor progression. Basal cell carcinoma and squamous cell carcinoma comprise types of nonmelanoma skin cancer. Evaluate the glycosaminoglycans profile and expression of heparanase in two human cell lines established in culture, immortalized skin keratinocyte (HaCaT) and squamous cell carcinoma (A431) and also investigate the expression of heparanase in basal cell carcinoma, squamous cell carcinoma and eyelid skin of individuals not affected by the disease (control). Glycosaminoglycans were quantified by electrophoresis and indirect ELISA method. The heparanase expression was analyzed by quantitative RT-PCR (qRTPCR). The A431 strain showed significant increase in the sulfated glycosaminoglycans, increased heparanase expression and decreased hyaluronic acid, comparing to the HaCaT lineage. The mRNA expression of heparanase was significantly higher in Basal cell carcinoma and squamous cell carcinoma compared with control skin samples. It was also observed increased heparanase expression in squamous cell carcinoma compared to the Basal cell carcinoma. The glycosaminoglycans profile, as well as heparanase expression are different between HaCaT and A431 cell lines. The increased expression of heparanase in Basal cell carcinoma and squamous cell carcinoma suggests that this enzyme could be a marker for the diagnosis of such types of non-melanoma cancers, and may be useful as a target molecule for future alternative treatment.